Menu Close

Insurers balk at paying for Biogen’s $56,000-a-year Alzheimer’s treatment

U.S. health insurers say they want more proof before paying for Biogen Inc.’s Aduhelm, stalling sales of the costly new Alzheimer’s therapy that the company hailed as a breakthrough for patients.